Dr Ru-Dee Ting is a consultant general and interventional cardiologist at Sydney Cardiology. He is the head of the department of Cardiology at Sydney Adventist Hospital.
Dr Ting specialises in coronary angioplasty, rotational atherectomy, diagnostic intracoronary imaging, right heart catheterisation and haemodynamic testing. He is proficient in both radial and femoral access coronary angiography. Dr Ting also has expertise in structural intervention including transcatheter aortic valve implantation, atrial septal defect and patent foramen ovale closure and transcatheter mitral valve repair. Dr Ting also performs transthoracic echocardiography, exercise stress echo testing, holter and event monitoring, and 24hr blood pressure monitoring.
Dr Ting obtained his degree in Medicine and Surgery at the University of Melbourne. He trained in cardiology at the Royal Prince Alfred Hospital and completed an interventional fellowship at St Michael’s Hospital, University of Toronto, Canada. He is a fellow of the Royal Australasian College of Physicians and a fellow of the Cardiac Society of Australia and New Zealand.
In addition, Dr Ting holds a PhD and a Masters of Clinical Trials from the University of Sydney. He undertook translational research at both the NHMRC Clinical Trials Centre and the Heart Research Institute. He was the recipient of a NHMRC postgraduate scholarship as well as a NHMRC CTC PhD research scholarship for his work examining the impact of renal disease on cardiovascular risk and the effect of fenofibrate on the microvascular complications of diabetes. He has published in various medical journals and has presented his work at numerous conferences both locally and internationally.
He is a clinical lecturer at the University of Sydney clinical school and a senior clinical lecturer at the Macquarie University clinical school, being involved with undergraduate education. He also delivers lectures extensively to primary care physicians in the areas of preventative cardiology, coronary heart disease and arrhythmia.
Dr Ting has admitting rights at Sydney Adventist Hospital, Norwest Private Hospital and Macquarie University Private Hospital.
Procedures & Conditions
- Transcatheter Aortic Valve Implantation (TAVI)
- MitraClip Transcatheter Mitral Valve Repair Device
- Atrial Septal Defect (ASD) Closures
- Patent Foramen Ovale (PFO) Closures
- Percutaneous Coronary Intervention (PCI)
- Aortic Stenosis
- Structural Heart Disease
Interventional Cardiologist; Head of CardiologySydney Adventist Hospital Present
Interventional CardiologistMacquarie University Hospital Present
Interventional CardiologistNorwest Private Hospital Present
Clinical Senior LecturerMacquarie University 2016-Present
Clinical LecturerUniversity of Sydney 2016-Present
Interventional CardiologistSydney Cardiology Group 2015-Present
Structural Heart Disease FellowSt Michael's Hospital, Toronto 2013-2014
Fellowship in CardiologyRoyal Australasian College of Physicians 2010
Cardiology Advanced TrainingRoyal Prince Alfred Hospital 2008-2009
Honorary Associate - Clinical Research & Epidemiology at the NHMRC Clinical Trials CentreThe University of Sydney 2007-2009
Advanced Trainee General MedicineRoyal Prince Alfred Hospital 2007
FRACP BPT3Royal Prince Alfred Hospital 2006
FRACP BPT2Royal Melbourne Hospital 2005
Research & Publications
1. R. Ting and P.L Drury et al. “Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study”, Diabetologia 2011; 54(1): 32-43
2. R. Ting and T.M.E Davis et al. “Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study”, Diabetologia 2011; 54(2): 28090
3. R. Ting and A.C. Keech et al. “Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD study”, Diabetes Care 2012; 35:218-25
4. G.J. Hankey et al. “Rates and predictors of risk of stroke and its subtypes in diabetes: a prospective observational study”, Journal of Neurology, Neurosurgery and Psychiatry 2013; 84(3):281-7
5. R. Ting, A.C. Keech. “Fenofibrate and renal disease: clinical effects in diabetes”, Clinical Lipidology 2013; 8 (6): 669–80
6. R. Ting et al. “Repatriation to Referral Hospital After Reperfusion of STEMI Patients Transferred for Primary Percutaneous Coronary Intervention: Insights of a Canadian Regional STEMI Care System”, American Heart Journal, in-press.
7. “A Systemic Review and Meta-Analysis of Two-Stent Techniques for the Treatment of Coronary Bifurcation Lesions”. Society for Cardiovascular Angiography and Interventions 2014 Scientific Sessions (May), Las Vegas, USA. Catheterization and Cardiovascular Interventions 2014; 83 (S1): S59.
8. Challenging Case: “A Case of Extra Backup Being Insufficient”. Transcatheter Cardiovascular Therapeutics Conference (September), Washington, DC, USA
9. “A Systemic Review and Meta-Analysis of Two-Stent Techniques for the Treatment of Coronary Bifurcation Lesions”. Canadian Cardiovascular Congress, Vancouver, Canada (October)
10. “Risk Predictors of Lower-limb Amputation in Patients with Type 2 Diabetes Mellitus in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study”. Cardiac Society of Australia and New Zealand Annual Scientific Meeting (Aug), Perth Australia
11. “Cardiovascular and Renal Safety of Fenofibrate in the FIELD Study”. European Atherosclerotic Society Congress (June), Hamburg Germany. Atherosclerosis supplements 2010; 11(2): 219
12. “Fenofibrate Reduces Peripheral Neuropathy in Type 2 Diabetes: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study”. European Atherosclerotic Society Congress (June), Hamburg Germany. Atherosclerosis supplements 2010; 11(2): 219-20
13. “Clinical and Biochemical Indicators and Predictors of microvascular complications of type 2 diabetes mellitus: the FIELD study”. American Heart Association Annual Scientific Meeting (Nov), Orlando USA
14. “Clinical and Biochemical Indicators of microvascular complications of type 2 diabetes mellitus: the FIELD study”. Australian Diabetes Society Annual Scientific Meeting (Aug), Adelaide AustraliaView More
- “Renal disease: Bedside to Bench”, Vascular Risk Masterclass (Nov 2011), Melbourne Australia.
- “Effect of Fenofibrate on Cardiovascular Events According to Changes in Plasma Creatinine Levels during the Pre-Randomization Period: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study”, American Society of Nephrology Kidney Week (Nov 2011), Philadelphia, USA
- “Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes mellitus and renal impairment – the FIELD study”, European Society of Cardiology Annual Scientific Congress (Aug 2011)
- “Rates and risk predictors of stroke and its subtypes among people with diabetes mellitus”, European Society of Cardiology Annual Scientific Congress (Aug 2011)
- “Cardiovascular Risk, Renal Status and Fenofibrate Safety in the FIELD Study”, Cardiac Society of Australia and New Zealand Annual Scientific Meeting (Aug 2011), Perth Australia
- “Effects of Fenofibrate on renal endpoints and safety issues”, NHMRC CTC visiting scientist seminar (Apr 2011), Sydney
- “Effects of fenofibrate on measures of renal function in type 2 diabetes mellitus: the FIELD study” Vascular Risk Masterclass (Nov 2010), Melbourne Australia.
- “Renal and Cardiovascular Safety of Fenofibrate in the FIELD Study”. Australian Diabetes Society Annual Scientific Meeting (Sept 2010), Sydney Australia.
- “Effects of fenofibrate on measures of renal function in type 2 diabetes mellitus: the FIELD study” Vascular Risk Masterclass (Nov 2009), Melbourne Australia.